{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:13:04Z","timestamp":1793387584993,"version":"4.5.0"},"reference-count":182,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005825","name":"USDA National Institute of Food and Agriculture","doi-asserted-by":"publisher","award":["2024-67012-42721"],"award-info":[{"award-number":["2024-67012-42721"]}],"id":[{"id":"10.13039\/100005825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The development of viral vaccines faces persistent scientific and logistical challenges, particularly in the wake of the COVID-19 pandemic. This review critically examines emerging strategies to overcome key barriers in viral vaccine design and deployment. We focus on four major areas: (1) structure-guided antigen engineering to stabilize conformations; (2) the mRNA platform and its delivery system; (3) advanced adjuvant systems that enhance cellular and humoral immunity; and (4) approaches to mitigate immune imprinting and antigenic variability, such as chimeric antigens and glycan shielding. We also explore anti-idiotypic vaccination strategies and the limitations of current animal models in predicting human immune responses. In addition, to address vaccine hesitancy and inequitable access, we advocate for global collaboration in manufacturing, distribution, and public education to ensure inclusive immunization strategies. By integrating molecular insights with platform technologies, we aim to inform the rational design of future vaccines with improved efficacy and public acceptance.<\/jats:p>","DOI":"10.3390\/vaccines13090979","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T13:03:02Z","timestamp":1758114182000},"page":"979","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel Strategies for Developing Next-Generation Vaccines to Combat Infectious Viral Diseases"],"prefix":"10.3390","volume":"13","author":[{"given":"Fangfeng","family":"Yuan","sequence":"first","affiliation":[{"name":"Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Bluth","sequence":"additional","affiliation":[{"name":"Blood Transfusion and Donor Services, Maimonides Medical Center, Brooklyn, NY 11219, USA"},{"name":"Department of Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/imr.12099","article-title":"Immunity to viruses: Learning from successful human vaccines","volume":"255","author":"Pulendran","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_2","unstructured":"Amanna, I.J., and Slifka, M.K. (2020). Successful vaccines. Vaccination Strategies Against Highly Variable Pathogens, Springer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1586\/14760584.2015.1001750","article-title":"Polio endgame: The global introduction of inactivated polio vaccine","volume":"14","author":"Patel","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Saylor, K., Gillam, F., Lohneis, T., and Zhang, C. (2020). Designs of antigen structure and composition for improved protein-based vaccine efficacy. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00283"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-based human papillomavirus (HPV) vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/infdis\/161.1.27","article-title":"A recombinant human adenovirus vaccine against rabies","volume":"161","author":"Prevec","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41564-023-01505-9","article-title":"Immune imprinting and next-generation coronavirus vaccines","volume":"8","author":"Huang","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rock, D.L. (2021). Thoughts on African Swine Fever Vaccines. Viruses, 13.","DOI":"10.3390\/v13050943"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vetmic.2016.10.003","article-title":"Challenges for African swine fever vaccine development\u2014\u201c\u2026 perhaps the end of the beginning\u201d","volume":"206","author":"Rock","year":"2017","journal-title":"Vet. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/OLQ.0000000000000831","article-title":"Syphilis vaccine development: Requirements, challenges, and opportunities","volume":"45","author":"Cameron","year":"2018","journal-title":"Sex. Transm. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e00094-23","DOI":"10.1128\/cmr.00094-23","article-title":"Neisseria gonorrhoeae vaccines: A contemporary overview","volume":"37","author":"Williams","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Ellis","year":"2021","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eade4790","DOI":"10.1126\/scitranslmed.ade4790","article-title":"An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults","volume":"15","author":"Widge","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/jiab532","article-title":"Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: Intramuscular results","volume":"226","author":"Withanage","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Leroux-Roels, I., Waerlop, G., Tourneur, J., De Boever, F., Maes, C., Bruhwyler, J., Guyon-Gellin, D., Moris, P., Del Campo, J., and Willems, P. (2022). Randomized, double-blind, reference-controlled, phase 2a study evaluating the immunogenicity and safety of OVX836, a nucleoprotein-based influenza vaccine. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.852904"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ingrole, R.S.J., Shakya, A.K., Joshi, G., Lee, C.H., Nesovic, L.D., Compans, R.W., and Gill, H.S. (2025). Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization. Nat. Biomed. Eng.","DOI":"10.1038\/s41551-025-01451-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-024-00952-7","article-title":"Sequential immunization with chimeric hemagglutinin \u0394NS1 attenuated influenza vaccines induces broad humoral and cellular immunity","volume":"9","author":"Rathnasinghe","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Singleton, E.V., Gates, C.J., David, S.C., Hirst, T.R., Davies, J.B., and Alsharifi, M. (2021). Enhanced Immunogenicity of a Whole-Inactivated Influenza A Virus Vaccine Using Optimised Irradiation Conditions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.761632"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1016\/j.vaccine.2023.05.074","article-title":"Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model","volume":"41","author":"Ma","year":"2023","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: Interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1093\/infdis\/jiae329","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: Final results from a phase 1\/2 randomized trial","volume":"231","author":"Ananworanich","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: Phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/S2666-5247(22)00337-8","article-title":"First-in-human use of a modular capsid virus-like vaccine platform: An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2","volume":"4","author":"Smit","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103349","DOI":"10.1016\/j.eclinm.2025.103349","article-title":"Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: A randomized, active-controlled, Phase 3 trial","volume":"86","author":"Rumyantsev","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1093\/infdis\/jiae081","article-title":"Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults","volume":"230","author":"Shaw","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1473-3099(23)00068-3","article-title":"Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: An open-label, non-randomised, first-in-human phase 1 clinical trial","volume":"23","author":"Jenkin","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S2213-2600(21)00098-9","article-title":"Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: A phase 1, randomised, open-label, dose-escalation clinical trial","volume":"9","author":"Ruckwardt","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41591-025-03591-0","article-title":"mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: A phase 1\/2 trial","volume":"31","author":"Ananworanich","year":"2025","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"August, A., Shaw, C.A., Lee, H., Knightly, C., Kalidindia, S., Chu, L., Essink, B.J., Seger, W., Zaks, T., and Smolenov, I. (2022). Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults, Oxford University Press.","DOI":"10.1093\/ofid\/ofac206"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102209","DOI":"10.1016\/j.coi.2022.102209","article-title":"Principles and practical applications of structure-based vaccine design","volume":"77","author":"Byrne","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41541-023-00734-7","article-title":"The road to approved vaccines for respiratory syncytial virus","volume":"8","author":"Ruckwardt","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"114518","DOI":"10.1016\/j.celrep.2024.114518","article-title":"Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ellis, D., Brunette, N., Crawford, K.H.D., Walls, A.C., Pham, M.N., Chen, C., Herpoldt, K.-L., Fiala, B., Murphy, M., and Pettie, D. (2021). Stabilization of the SARS-CoV-2 spike receptor-binding domain using deep mutational scanning and structure-based design. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.710263"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/j.immuni.2023.11.009","article-title":"RNA vaccines: A transformational advance","volume":"56","author":"Brown","year":"2023","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases\u2014Advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ramezani-Rad, P., Marina-Zarate, E., Maiorino, L., Myers, A., Michaels, K.K., Pires, I.S., Bloom, N.I., Lopez, P.G., Cottrell, C.A., and Burton, I. (2024). Dose-dependent regulation of immune memory responses against HIV by saponin monophosphoryl lipid A nanoparticle adjuvant. bioRxiv.","DOI":"10.1101\/2024.07.31.604373"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41587-024-02393-y","article-title":"Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation","volume":"43","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41587-022-01525-6","article-title":"An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts","volume":"41","author":"Dousis","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113910","DOI":"10.1016\/j.ejmech.2021.113910","article-title":"The nano delivery systems and applications of mRNA","volume":"227","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.apsb.2023.10.012","article-title":"Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design","volume":"14","author":"Yan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"28256","DOI":"10.1039\/D0CP05111J","article-title":"DOPC versus DOPE as a helper lipid for gene-therapies: Molecular dynamics simulations with DLin-MC3-DMA","volume":"22","author":"Ermilova","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., and Piel, G. (2023). Effect of PEG anchor and serum on lipid nanoparticles: Development of a nanoparticles tracking method. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020597"},{"key":"ref_55","unstructured":"Kafil, V., and Omidi, Y. (2011). Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells. BioImpacts BI, 1."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Pateev, I., Seregina, K., Ivanov, R., and Reshetnikov, V. (2024). Biodistribution of RNA Vaccines and of Their Products: Evidence from Human and Animal Studies. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010059"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41573-024-01041-z","article-title":"Advanced technologies for the development of infectious disease vaccines","volume":"23","author":"Gupta","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1016\/j.vaccine.2021.10.019","article-title":"Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system","volume":"39","author":"Myers","year":"2021","journal-title":"Vaccine"},{"key":"ref_62","first-page":"e41","article-title":"Safety and adverse events related to COVID-19 mRNA vaccines; a systematic review","volume":"10","author":"SeyedAlinaghi","year":"2022","journal-title":"Arch. Acad. Emerg. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Senti","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_65","first-page":"433","article-title":"Differences in innate immune response between man and mouse","volume":"34","author":"Zschaler","year":"2014","journal-title":"Crit. Rev.\u2122 Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1128\/JVI.77.22.12022-12032.2003","article-title":"DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell-and mammalian cell-derived viruses","volume":"77","author":"Klimstra","year":"2003","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"ref_71","first-page":"552","article-title":"Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers","volume":"7","author":"Garanger","year":"2007","journal-title":"Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents)"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Schottelius, M., Herrmann, K., and Lapa, C. (2021). In vivo targeting of CXCR4\u2014New horizons. Cancers, 13.","DOI":"10.3390\/cancers13235920"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2309472120","DOI":"10.1073\/pnas.2309472120","article-title":"Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","article-title":"Combinatorial development of nebulized mRNA delivery formulations for the lungs","volume":"19","author":"Jiang","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: Mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants\u2014In retrospect and prospect","volume":"22","author":"Lindblad","year":"2004","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tips.2009.03.005","article-title":"Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants","volume":"30","author":"Aimanianda","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wilkins, A.L., Kazmin, D., Napolitani, G., Clutterbuck, E.A., Pulendran, B., Siegrist, C.-A., and Pollard, A.J. (2017). AS03-and MF59-adjuvanted influenza vaccines in children. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01760"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3181\/00379727-49-13625","article-title":"Sensitization to horse serum by means of adjuvants","volume":"49","author":"Freund","year":"1942","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"12294","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants","volume":"111","author":"Maisonneuve","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1126\/science.1138963","article-title":"The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4","volume":"316","author":"Cekic","year":"2007","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/1566524023362159","article-title":"Toll-like receptor 9, CpG DNA and innate immunity","volume":"2","author":"Ashkar","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.intimp.2019.01.024","article-title":"Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo","volume":"69","author":"Yang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Castrodeza-Sanz, J., Sanz-Mu\u00f1oz, I., and Eiros, J.M. (2023). Adjuvants for COVID-19 vaccines. Vaccines, 11.","DOI":"10.3390\/vaccines11050902"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/jir769","article-title":"GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults","volume":"205","author":"Behzad","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","article-title":"Adjuvant system AS01: From mode of action to effective vaccines","volume":"23","author":"Roman","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acsnano.4c12237","article-title":"Activating the cGAS-STING Pathway by Manganese-Based Nanoparticles Combined with Platinum-Based Nanoparticles for Enhanced Ovarian Cancer Immunotherapy","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Yan, H., and Chen, W. (2021). The promise and challenges of cyclic dinucleotides as molecular adjuvants for vaccine development. Vaccines, 9.","DOI":"10.3390\/vaccines9080917"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, B., Yu, W., Jiang, H., Meng, X., Tang, D., and Liu, D. (2024). Clinical applications of STING agonists in cancer immunotherapy: Current progress and future prospects. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1485546"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA. 2.75. 2, BQ. 1.1 and XBB. 1 by parental mRNA vaccine or a BA. 5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41591-023-02517-y","article-title":"Original SARS-CoV-2 monovalent and Omicron BA. 4\/BA. 5 bivalent COVID-19 mRNA vaccines: Phase 2\/3 trial interim results","volume":"29","author":"Chalkias","year":"2023","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","article-title":"Predicting the efficacy of variant-modified COVID-19 vaccine boosters","volume":"29","author":"Khoury","year":"2023","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"Nielsen","year":"2022","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"110561","DOI":"10.1016\/j.celrep.2022.110561","article-title":"Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting","volume":"38","author":"Hauser","year":"2022","journal-title":"Cell Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(22)00792-7","article-title":"Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation","volume":"23","author":"Hoffmann","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e01070-22","DOI":"10.1128\/jvi.01070-22","article-title":"Antigenic landscape analysis of individuals vaccinated with a universal influenza virus vaccine candidate reveals induction of cross-subtype immunity","volume":"97","author":"Meade","year":"2023","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-019-0126-4","article-title":"A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains","volume":"4","author":"Broecker","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.00333-19","article-title":"Development of influenza B universal vaccine candidates using the \u201cmosaic\u201d hemagglutinin approach","volume":"93","author":"Sun","year":"2019","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Carnell, G.W., Billmeier, M., Vishwanath, S., Suau Sans, M., Wein, H., George, C.L., Neckermann, P., Del Rosario, J.M.M., Sampson, A.T., and Einhauser, S. (2023). Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1118523"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The quest for a universal flu vaccine: Headless HA 2.0","volume":"18","author":"Krammer","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses","volume":"20","author":"Kanekiyo","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.vaccine.2019.03.018","article-title":"A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains","volume":"37","author":"Ross","year":"2019","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e01652-21","DOI":"10.1128\/jvi.01652-21","article-title":"Bivalent H1 and H3 COBRA recombinant hemagglutinin vaccines elicit seroprotective antibodies against H1N1 and H3N2 influenza viruses from 2009 to 2019","volume":"96","author":"Allen","year":"2022","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41541-019-0098-4","article-title":"OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes","volume":"4","author":"Pizzorno","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1473-3099(23)00351-1","article-title":"Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"23","author":"Willems","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"ofae631.188","DOI":"10.1093\/ofid\/ofae631.188","article-title":"593. Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine","volume":"12","author":"Han","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ni.2914","article-title":"CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype","volume":"15","author":"Sadanand","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/375334a0","article-title":"Antigen-induced B-cell death and elimination during germinal-centre immune responses","volume":"375","author":"Shokat","year":"1995","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/375331a0","article-title":"Soluble antigen can cause enhanced apoptosis of germinal-centre B cells","volume":"375","author":"Pulendran","year":"1995","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.celrep.2017.12.014","article-title":"Targeted elimination of immunodominant B cells drives the germinal center reaction toward subdominant epitopes","volume":"21","author":"Silva","year":"2017","journal-title":"Cell Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.celrep.2019.09.058","article-title":"Injection of antibodies against immunodominant epitopes tunes germinal centers to generate broadly neutralizing antibodies","volume":"29","year":"2019","journal-title":"Cell Rep."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Lee, K.-W., Yam, J.W., and Mao, X. (2023). Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 12.","DOI":"10.3390\/cells12172147"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: Implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri2780","article-title":"Cross-priming in health and disease","volume":"10","author":"Kurts","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.it.2011.10.007","article-title":"Boosting antibody responses by targeting antigens to dendritic cells","volume":"33","author":"Caminschi","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nmat2357","article-title":"Infection-mimicking materials to program dendritic cells in situ","volume":"8","author":"Ali","year":"2009","journal-title":"Nat. Mater."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2104362","DOI":"10.1002\/adma.202104362","article-title":"Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2","volume":"33","author":"Gale","year":"2021","journal-title":"Adv. Mater."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"ref_123","first-page":"437","article-title":"Anti-IgE autoantibodies: A possible specific feedback on the cytokine network in allergy?","volume":"3","author":"Stadler","year":"1992","journal-title":"Eur. Cytokine Netw."},{"key":"ref_124","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125","author":"Jerne","year":"1974","journal-title":"Ann. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1073\/pnas.80.3.830","article-title":"Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy","volume":"80","author":"Reed","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/humrep\/14.3.650","article-title":"Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: Analysis of anti-idiotypic antibodies directed against autologous T-cell receptors","volume":"14","author":"Ito","year":"1999","journal-title":"Hum. Reprod."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02918364","article-title":"Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients","volume":"12","author":"Reed","year":"1993","journal-title":"Immunol. Res."},{"key":"ref_128","first-page":"34","article-title":"Idiotypic vaccination as therapy for multiple myeloma","volume":"36","author":"Kwak","year":"1999","journal-title":"Semin. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1172\/JCI118039","article-title":"Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine","volume":"96","author":"Foon","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1089\/aid.1992.8.1091","article-title":"Anti-CD4 Anti-Idiotype Antibodies in Volunteers Immunized with rgp 160 of HIV-1 or Infected with HIV-1","volume":"8","author":"Keay","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4049\/jimmunol.156.2.826","article-title":"CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination","volume":"156","author":"Deckert","year":"1996","journal-title":"J. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1073\/pnas.89.7.2546","article-title":"Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys","volume":"89","author":"Kang","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Soodeen, S., and Justiz-Vaillant, A. (2025). Exploring Anti-Idiotypic HIV Vaccines through Oral Immunisation and Immunological Network Theory. arXiv.","DOI":"10.20944\/preprints202505.2043.v1"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Stanova, A.K., Ryabkova, V.A., Tillib, S.V., Utekhin, V.J., Churilov, L.P., and Shoenfeld, Y. (2020). Anti-idiotypic agonistic antibodies: Candidates for the role of universal remedy. Antibodies, 9.","DOI":"10.3390\/antib9020019"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1096\/fasebj.9.1.7821758","article-title":"Anti-idiotypic antibodies: Biological function and structural studies","volume":"9","author":"Pan","year":"1995","journal-title":"FASEB J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1056\/NEJMcibr2113694","article-title":"A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination","volume":"386","author":"Murphy","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Junker, F., Gordon, J., and Qureshi, O. (2020). Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01393"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/mi.2011.36","article-title":"The human immunoglobulin A Fc receptor Fc\u03b1RI: A multifaceted regulator of mucosal immunity","volume":"4","author":"Bakema","year":"2011","journal-title":"Mucosal Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1084\/jem.20091107","article-title":"Identity of the elusive IgM Fc receptor (Fc\u03bcR) in humans","volume":"206","author":"Kubagawa","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"s49","DOI":"10.1111\/1523-1747.ep12875051","article-title":"Fc Receptors for IgE and Interleukin-4 Induced IgE and IgG4 Secretion","volume":"94","author":"Spiegelberg","year":"1990","journal-title":"J. Investig. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2249.2010.04265.x","article-title":"Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris","volume":"162","author":"Mimouni","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V92.4.1184","article-title":"Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin\u2019s Lymphoma Without Eradicating the Malignant Clone","volume":"92","author":"Davis","year":"1998","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-013-1413-y","article-title":"Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response","volume":"62","author":"Lode","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/bcr2826","article-title":"Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice","volume":"13","author":"Ladjemi","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1054\/bjoc.2000.1431","article-title":"A transgenic mouse model for tumour immunotherapy: Induction of an anti-idiotype response to human MUC1","volume":"83","author":"Wilkinson","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e01650-23","DOI":"10.1128\/jvi.01650-23","article-title":"A novel strategy for an anti-idiotype vaccine: Nanobody mimicking neutralization epitope of porcine circovirus type 2","volume":"98","author":"Deng","year":"2024","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Kohler, H., Pashov, A., and Kieber-Emmons, T. (2019). The Promise of Anti-idiotype Revisited. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00808"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"FSO648","DOI":"10.2144\/fsoa-2020-0142","article-title":"Immunomodulatory Potential of anti-idiotypic Antibodies for the Treatment of Autoimmune Diseases","volume":"7","author":"Pan","year":"2021","journal-title":"Future Sci. OA"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molimm.2021.04.010","article-title":"Non-human primate models of human respiratory infections","volume":"135","author":"Lemaitre","year":"2021","journal-title":"Mol. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Santaniello, A., Perruolo, G., Cristiano, S., Agognon, A.L., Cabaro, S., Amato, A., Dipineto, L., Borrelli, L., Formisano, P., and Fioretti, A. (2023). SARS-CoV-2 Affects Both Humans and Animals: What Is the Potential Transmission Risk? A Literature Review. Microorganisms, 11.","DOI":"10.3390\/microorganisms11020514"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1038\/s41596-020-00403-2","article-title":"Genetically modified mouse models to help fight COVID-19","volume":"15","author":"Gurumurthy","year":"2020","journal-title":"Nat. Protoc."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Yinda, C.K., Port, J.R., Bushmaker, T., Offei Owusu, I., Purushotham, J.N., Avanzato, V.A., Fischer, R.J., Schulz, J.E., Holbrook, M.G., and Hebner, M.J. (2021). K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009195"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","article-title":"A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","volume":"586","author":"Leist","year":"2020","journal-title":"Nature"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2353\/ajpath.2008.070776","article-title":"Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis","volume":"172","author":"Schulte","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-022-01087-8","article-title":"Animal models for COVID-19: Advances, gaps and perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Wang, S., Li, L., Yan, F., Gao, Y., Yang, S., and Xia, X. (2021). COVID-19 animal models and vaccines: Current landscape and future prospects. Vaccines, 9.","DOI":"10.3390\/vaccines9101082"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/v20801530","article-title":"Animal Models for Influenza Virus Pathogenesis and Transmission","volume":"2","author":"Bouvier","year":"2010","journal-title":"Viruses"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2021.03.004","article-title":"SARS-CoV-2 in animals: From potential hosts to animal models","volume":"110","author":"Michelitsch","year":"2021","journal-title":"Adv. Virus Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00281-016-0580-2","article-title":"Influenza pathogenicity during pregnancy in women and animal models","volume":"38","author":"Engels","year":"2016","journal-title":"Semin Immunopathol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1016\/j.cub.2021.01.006","article-title":"Herd immunity","volume":"31","author":"Ashby","year":"2021","journal-title":"Curr. Biol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Clemente-Su\u00e1rez, V.J., Horme\u00f1o-Holgado, A., Jim\u00e9nez, M., Benitez-Agudelo, J.C., Navarro-Jim\u00e9nez, E., Perez-Palencia, N., Maestre-Serrano, R., Laborde-C\u00e1rdenas, C.C., and Tornero-Aguilera, J.F. (2020). Dynamics of population immunity due to the herd effect in the COVID-19 pandemic. Vaccines, 8.","DOI":"10.3390\/vaccines8020236"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.annemergmed.2022.01.040","article-title":"Factors associated with parental acceptance of COVID-19 vaccination: A multicenter pediatric emergency department cross-sectional analysis","volume":"80","author":"Baumann","year":"2022","journal-title":"Ann. Emerg. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2313860","DOI":"10.1080\/21645515.2024.2313860","article-title":"Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review","volume":"20","author":"Wong","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Bujaki","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Sayedahmed, E.E., Elkashif, A., Alhashimi, M., Sambhara, S., and Mittal, S.K. (2020). Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8040574"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41467-023-37697-1","article-title":"An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters","volume":"14","author":"Deng","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","article-title":"Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Zhu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Trimzi, M.A., and Ham, Y.-B. (2021). A needle-free jet injection system for controlled release and repeated biopharmaceutical delivery. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111770"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm0103-99","article-title":"Can needle-free administration of vaccines become the norm in global immunization?","volume":"9","author":"Levine","year":"2003","journal-title":"Nat. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nri1728","article-title":"Immunization without needles","volume":"5","author":"Mitragotri","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd2076","article-title":"Current status and future prospects of needle-free liquid jet injectors","volume":"5","author":"Mitragotri","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1080\/17425247.2024.2351928","article-title":"3D bioprinted microneedles: Merging drug delivery and scaffold science for tissue-specific applications","volume":"21","author":"Govender","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"106288","DOI":"10.1016\/j.jddst.2024.106288","article-title":"Revolutionizing microneedle array fabrication using additive manufacturing technologies: Potential applications and clinical translation","volume":"101","author":"Nadda","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Olowe, M., Parupelli, S.K., and Desai, S. (2022). A Review of 3D-Printing of Microneedles. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122693"},{"key":"ref_180","first-page":"222","article-title":"Design and fabrication of customizable microneedles enabled by 3D printing for biomedical applications","volume":"32","author":"Loh","year":"2024","journal-title":"Bioact. Mater."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/jmv.27485","article-title":"Host factors and vaccine efficacy: Implications for COVID-19 vaccines","volume":"94","author":"Falahi","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e00084-18","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/979\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:54Z","timestamp":1760035614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":182,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vaccines13090979"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13090979","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}